User login
Background
This study aims to evaluate the impact of treatment facility type on the long-term survival rates of patients with pancreatic neuroendocrine tumors, as well as the demographic and treatment differences between these groups. Pancreatic neuroendocrine tumors are a rare form of pancreatic cancer with a highly variable survival rate. While existing cancer research indicates that patients treated at academic facilities generally experience improved survival outcomes compared to low income patients, there is little research on this topic in the context of pancreatic neuroendocrine tumors.
Methods
The National Cancer Database (NCDB) was used to identify patients diagnosed with pancreatic neuroendocrine carcinoma from 2004 to 2019 using the histology code 8246 as assigned by the Commission on Cancer Accreditation program. Kaplan-Meier, ANOVA, and Chi-Square tests were performed. Data was analyzed using SPSS version 27 and statistical significance was set at α = 0.05.
Results
In this analysis of 13,987 patients, 6,957 (49.7%) were treated at academic facilities, while 7,012 (50.3%) were treated at non-academic facilities. Patients treated at academic facilities experienced a significantly increased mean survival rate of 100.5 months following diagnosis compared to the 75.6 month mean survival rate of patients treated at non-academic facilities (p< 0.05). Additionally, patients treated at academic facilities were more likely to be black, have private insurance, undergo surgery, and live in a metropolitan area with a population larger than 1 million (p< 0.05). Conversely, patients treated at non-academic facilities experienced a worse 30-day and 90-day mortality, had a higher average Charlson-Deyo Comorbidity Index, and lived closer to their treatment facility (p< 0.05). Patients’ income did not differ significantly.
Conclusions
This study showed that patients with pancreatic neuroendocrine carcinomas treated at academic facilities experienced a significantly improved overall survival rate compared to low income patients. This disparity may be attributed to differences in rates of surgical intervention or insurance status, among other factors. These observations are based on correlational data, and they underscore the necessity for further investigation to establish causality.
Background
This study aims to evaluate the impact of treatment facility type on the long-term survival rates of patients with pancreatic neuroendocrine tumors, as well as the demographic and treatment differences between these groups. Pancreatic neuroendocrine tumors are a rare form of pancreatic cancer with a highly variable survival rate. While existing cancer research indicates that patients treated at academic facilities generally experience improved survival outcomes compared to low income patients, there is little research on this topic in the context of pancreatic neuroendocrine tumors.
Methods
The National Cancer Database (NCDB) was used to identify patients diagnosed with pancreatic neuroendocrine carcinoma from 2004 to 2019 using the histology code 8246 as assigned by the Commission on Cancer Accreditation program. Kaplan-Meier, ANOVA, and Chi-Square tests were performed. Data was analyzed using SPSS version 27 and statistical significance was set at α = 0.05.
Results
In this analysis of 13,987 patients, 6,957 (49.7%) were treated at academic facilities, while 7,012 (50.3%) were treated at non-academic facilities. Patients treated at academic facilities experienced a significantly increased mean survival rate of 100.5 months following diagnosis compared to the 75.6 month mean survival rate of patients treated at non-academic facilities (p< 0.05). Additionally, patients treated at academic facilities were more likely to be black, have private insurance, undergo surgery, and live in a metropolitan area with a population larger than 1 million (p< 0.05). Conversely, patients treated at non-academic facilities experienced a worse 30-day and 90-day mortality, had a higher average Charlson-Deyo Comorbidity Index, and lived closer to their treatment facility (p< 0.05). Patients’ income did not differ significantly.
Conclusions
This study showed that patients with pancreatic neuroendocrine carcinomas treated at academic facilities experienced a significantly improved overall survival rate compared to low income patients. This disparity may be attributed to differences in rates of surgical intervention or insurance status, among other factors. These observations are based on correlational data, and they underscore the necessity for further investigation to establish causality.
Background
This study aims to evaluate the impact of treatment facility type on the long-term survival rates of patients with pancreatic neuroendocrine tumors, as well as the demographic and treatment differences between these groups. Pancreatic neuroendocrine tumors are a rare form of pancreatic cancer with a highly variable survival rate. While existing cancer research indicates that patients treated at academic facilities generally experience improved survival outcomes compared to low income patients, there is little research on this topic in the context of pancreatic neuroendocrine tumors.
Methods
The National Cancer Database (NCDB) was used to identify patients diagnosed with pancreatic neuroendocrine carcinoma from 2004 to 2019 using the histology code 8246 as assigned by the Commission on Cancer Accreditation program. Kaplan-Meier, ANOVA, and Chi-Square tests were performed. Data was analyzed using SPSS version 27 and statistical significance was set at α = 0.05.
Results
In this analysis of 13,987 patients, 6,957 (49.7%) were treated at academic facilities, while 7,012 (50.3%) were treated at non-academic facilities. Patients treated at academic facilities experienced a significantly increased mean survival rate of 100.5 months following diagnosis compared to the 75.6 month mean survival rate of patients treated at non-academic facilities (p< 0.05). Additionally, patients treated at academic facilities were more likely to be black, have private insurance, undergo surgery, and live in a metropolitan area with a population larger than 1 million (p< 0.05). Conversely, patients treated at non-academic facilities experienced a worse 30-day and 90-day mortality, had a higher average Charlson-Deyo Comorbidity Index, and lived closer to their treatment facility (p< 0.05). Patients’ income did not differ significantly.
Conclusions
This study showed that patients with pancreatic neuroendocrine carcinomas treated at academic facilities experienced a significantly improved overall survival rate compared to low income patients. This disparity may be attributed to differences in rates of surgical intervention or insurance status, among other factors. These observations are based on correlational data, and they underscore the necessity for further investigation to establish causality.